drugset / Trial / NCT06891066
A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
RandomizedParallel-groupOpen-labelTreatment
Summary
Investigators are trying to find better treatments for people with HIV-1. In this clinical study, investigators want to see how well a new treatment called ISL+ULO, taken once a week, works compared to an existing treatment called BIC/FTC/TAF, which is taken every day. Investigators will check how many people still have a high level of the virus in their blood after 24 weeks. The investigators also want to understand if the new treatment, MK-8591B, is safe and how well people can handle it.
Timeline
- Start
- 2025-04-14
- Primary completion
- 2027-08-10
- Completion
- 2031-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | BIC | Unknown | 50 mg | Oral |
| Comparator | FTC | Unknown | 200 mg | Oral |
| Subject | Islatravir | Other / unclassified | 2 mg | Oral |
| Comparator | TAF | Unknown | 25 mg | Oral |
| Subject | Ulonivirine | Small molecule | 200 mg | Oral |